VAM for secondary or extramedullary AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (called VAM) in people whose acute myeloid leukemia (AML) is either secondary (came from another blood disorder), therapy-related (caused by previous cancer treatment), or has spread outside the bone marrow (extramedullary disease). It is for patients who have not yet received any treatment for their AML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- Your AML is secondary, therapy-related, has spread outside the bone marrow (myeloid sarcoma), or you are 60 or older and considered fit for treatment
- You have not had any previous treatment for your AML
- Your heart, liver, and kidneys are working well (as shown by blood tests and a heart scan)
- You are able to take care of yourself (ECOG score 0-2) and do not have other active cancers or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (VAC) for people with acute myeloid leukemia (AML) who did not improve after standard VA treatment. It is for those who cannot have strong chemotherapy due to age or health problems.
This trial tests a new drug combination called VA against a standard chemotherapy (3+7) for older adults newly diagnosed with a type of AML that has changes in the NPM1 or IDH1/IDH2 genes. It aims to see which treatment works better and is safer.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people newly diagnosed with a type of acute myeloid leukemia (AML) that has developed after treatment with certain prior drugs (hypomethylating agents). The goal is to see if this combination is safe and effective.
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.